Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

John R. MacDonald, Daniel D. Von Hoff(Translational Genomics Research Institute), S F Chen, Daniel L. Dexter, Michael J. Kelner, G. Mangold(Texas Oncology), Trevor C. McMorris, Charles C. Muscoplat(Harper University Hospital)

PubMed

January 15, 1997

Cited by 109

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

|New England Journal of Medicine|2013|6.6k

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

|Journal of Clinical Oncology|1997|5.9k

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

|Annals of Oncology|1996|569

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

|Nature Communications|2015|484

Oral Pilocarpine for Post-Irradiation Xerostomia in Patients with Head and Neck Cancer

|New England Journal of Medicine|1993|483